Neuralstem Inc. (CUR) Given “Buy” Rating at Roth Capital
Neuralstem Inc. (NASDAQ:CUR)‘s stock had its “buy” rating reaffirmed by Roth Capital in a research note issued to investors on Friday. They presently have a $1.20 price objective on the stock. Roth Capital’s target price indicates a potential upside of 287.10% from the company’s previous close.
Separately, Brean Capital initiated coverage on Neuralstem in a research report on Wednesday, June 22nd. They set a “buy” rating and a $8.00 price target on the stock.
Shares of Neuralstem (NASDAQ:CUR) traded up 1.935% during midday trading on Friday, hitting $0.316. 670,061 shares of the stock were exchanged. Neuralstem has a 52-week low of $0.19 and a 52-week high of $1.96. The firm’s 50 day moving average price is $0.27 and its 200-day moving average price is $0.43. The stock’s market cap is $36.26 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/23/neuralstem-inc-cur-given-buy-rating-at-roth-capital.html
Neuralstem (NASDAQ:CUR) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The company had revenue of $2.50 million for the quarter, compared to the consensus estimate of $2.50 million. Neuralstem had a negative return on equity of 574.32% and a negative net margin of 173,849.97%. On average, equities research analysts expect that Neuralstem will post ($0.17) earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of CUR. Sabby Management LLC purchased a new position in Neuralstem during the second quarter worth about $1,893,000. Vanguard Group Inc. increased its position in Neuralstem by 21.8% in the second quarter. Vanguard Group Inc. now owns 3,384,138 shares of the company’s stock worth $984,000 after buying an additional 606,500 shares during the last quarter. Finally, Blair William & Co. IL purchased a new position in Neuralstem during the second quarter worth about $122,000. 18.20% of the stock is currently owned by institutional investors and hedge funds.
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Neuralstem Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.